

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Cochlear Limited
ABN	96 002 618 073

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Dr Christopher Graham Roberts
Date of last notice	25 February 2015

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct and indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	16,000 fully paid ordinary shares in Cochlear Limited. 12,000 fully paid ordinary shares in Cochlear Limited are held by Cabbit Pty Limited as trustee for two trusts of which Dr Roberts is a beneficiary. 4,000 fully paid ordinary shares in Cochlear Limited are held by Romaxis Pty Ltd as trustee for a trust of which Dr Roberts is a beneficiary.
Date of change	3 March 2015

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

No. of securities held prior to change	(a) 657,809 fully paid ordinary shares in Cochlear Limited (641,809 direct and 16,000 indirect) (b) 414,955 options each over one fully paid ordinary share in Cochlear Limited (unvested) (c) 2,781 short term incentive performance rights to fully paid ordinary shares ("STI Deferral Performance Rights") (a) 11,821 long term incentive performance rights to fully paid ordinary shares ("LTI Performance Rights")
Class	(a) fully paid ordinary shares (b) options over fully paid ordinary shares (which are subject to vesting criteria) (c) STI Deferral Performance Rights (d) LTI Performance Rights
Number acquired	Not applicable
Number disposed	46,540
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$74.36 per share
No. of securities held after change	(d) 611,269 fully paid ordinary shares in Cochlear Limited (595,269 direct and 16,000 indirect) (e) 414,955 options each over one fully paid ordinary share in Cochlear Limited (unvested) (f) 2,781 STI Deferral Performance Rights (g) 11,821 LTI Performance Rights
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	On-market trade

+ See chapter 19 for defined terms.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	Dr Roberts previously entered into a financing arrangement in relation to 46,540 fully paid ordinary shares in Cochlear Limited. The transaction included put and call options exercisable in 2015. The financing arrangement has been discharged and the shares are no longer subject to the financing arrangement.
Nature of interest	Direct
Name of registered holder (if issued securities)	Dr Christopher Graham Roberts
Date of change	3 March 2015
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	See "Detail of contract" above
Interest acquired	See "Detail of contract" above
Interest disposed	See "Detail of contract" above
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	Not applicable
Interest after change	Financing arrangements relating to 319,381 fully paid ordinary shares in Cochlear Limited, including 280,580 put and call options exercisable in 2015, and 38,801 put and call options exercisable in 2016.

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	Not applicable
If prior written clearance was provided, on what date was this provided?	Not applicable

⁺ See chapter 19 for defined terms.